Application of UHRF1 in preparation of synergist for treating tumors by CAR-T cells
By overexpressing UHRF1 in CAR-T cells, the problems of poor infiltration ability and short survival time of CAR-T cells in solid tumor treatment were solved, and their anti-tumor ability and therapeutic effect were significantly improved.
Patent Information
- Application Number
- CN202410899910.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-05
AI Technical Summary
In the treatment of solid tumors, CAR-T cells have problems such as toxicity in reflux, immune escape, short survival time and poor infiltration ability, resulting in poor treatment effect.
By modifying CAR-T cells, it overexpresses the epigenetic regulator UHRF1, which improves its infiltration ability and killing efficacy in tumors, and overexpression of UHRF1 is achieved through plasmids and recombinant lentiviral vectors.
It significantly enhances the anti-tumor ability of CAR-T cells, prolongs their survival time, improves infiltration and lethality in the tumor, and improves clinical treatment response.
Smart Images

Figure CN118987170A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and more specifically, to the application of UHRF1 in the preparation of a synergist for CAR-T cell therapy of tumors. Background Art
[0002] In recent years, immune cell therapy technology has achieved excellent results in clinical tumor treatment, especially the therapeutic effect of chimeric antigen receptor (CAR) T cells on blood tumors, which makes people look forward to the prospect of this technology. CAR-T therapy is to fuse scFv fragments that can recognize tumor-specific antigens such as CD19 and CEA to a transmembrane segment composed of a series of molecules involved in T cell activation such as CD28, CD137 and CD3-ζ, and transfect to transform the patient's T cells to express chimeric antigen receptors to achieve the purpose of targeted treatment.
[0003] Although CAR-T cell adoptive therapy has achieved significant therapeutic effects in the clinic and has shown great advantages in the clinical application of hematological tumors. However, there are still a series of side effects or problems, especially in the exploration of solid tumor treatment. There are many obstacles. First, the toxicity caused by CAR-T cell reinfusion, including diseases related to CAR-T cell immune activation and the subsequent induction of high-level cytokine release, such as cytokine storm, macrophage activation syndrome, etc., and CAR-T cells on the normal tissue cells expressing the target antigen The killing caused by the off-target effect caused by the killing; secondly, immune escape caused by tumor antigen loss or heterogeneity; thirdly, due to the long in vitro culture process or the inhibitory tumor microenvironment, the reinfused CAR-T cells have a short survival time in the body or cell exhaustion, resulting in weak killing ability; at the same time, the reinfused CAR-T cells also show poor infiltration ability in solid tumors.
[0004] How to make CAR-T cells show good killing and therapeutic effects in solid tumors is a problem of great practical significance and research value.
[0005] Ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1), as an epigenetic regulatory molecule, is considered to be the key to maintaining DNA methylation and plays a key role in important epigenetic modification events in DNA replication, such as the recruitment of DNA methyltransferase 1 (DNMT1). Summary of the invention
[0006] The purpose of the present invention is to overcome the deficiencies of the prior art and provide the application of UHRF1 in the preparation of a synergist for CAR-T cell therapy of tumors.
[0007] The applicant found that overexpression of the epigenetic regulatory factor UHRF1 increased the number of CEA-CAR-T cells infiltrating in mice, especially in tumors, reduced the exhaustion phenotype and apoptosis of CEA-CAR-T cells in mice, and enhanced the effect and killing ability of CEA-CAR-T cells in mice, that is, overexpression of UHRF1 increased the anti-tumor ability of CEA-CAR-T cells in mice. CAR-T cells that can resist T cell exhaustion and improve T cell infiltration and survival have high prospects in improving clinical responses.
[0008] The first objective of the present invention is to provide the use of UHRF1 protein in the preparation of a synergist for CAR-T cell therapy of tumors.
[0009] The second object of the present invention is to provide a plasmid for use in the preparation of CAR-T cell therapy tumor products.
[0010] The third object of the present invention is to provide a use of a recombinant lentivirus in the preparation of a CAR-T cell tumor treatment product.
[0011] The fourth object of the present invention is to provide a method for constructing CAR-T cells.
[0012] The fifth object of the present invention is to provide a CAR-T cell.
[0013] The sixth object of the present invention is to provide a method for constructing a CAR-T cell or an application of the CAR-T cell in preparing a product for preparing a tumor with a CAR-T cell.
[0014] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0015] The present invention transforms CAR-T cells to express CAR and overexpress UHRF1 at the same time, obtains CAR-T cells overexpressing UHRF1 and applies them to treat tumor-bearing Nod / scid immunodeficient mice. Compared with CAR-T cells that normally express UHRF1, CAR-T cells overexpressing UHRF1 have a more obvious killing effect on solid tumors, and the tumor size of mice in the CAR-T cell treatment group overexpressing UHRF1 is significantly smaller than that in the normal CAR-T cell treatment group.
[0016] Therefore, the present invention claims the following:
[0017] Application of UHRF1 protein in the preparation of enhancers for CAR-T cell therapy of tumors.
[0018] The accession number of the UHRF1 in the NCBI database is: NM_001290051.2.
[0019] Preferably, the enhancer increases the proliferation ability of CAR-T cells.
[0020] Preferably, the enhancer increases the immune response of CAR-T cells.
[0021] Preferably, the enhancer improves the effector killing function of CAR-T cells.
[0022] Preferably, the enhancer improves the survival ability of CAR-T cells.
[0023] Preferably, the CAR-T cells are CD8 + T cell subsets.
[0024] Preferably, the CAR-T cells are CAR-T cells targeting carcinoembryonic antigen CEA.
[0025] Preferably, the tumor is a solid tumor.
[0026] The present invention also claims protection for the use of a plasmid in the preparation of a product for CAR-T cell therapy of tumors, wherein the plasmid contains a nucleic acid molecule encoding a UHRF1 protein and a nucleic acid molecule encoding a CAR chimeric antigen receptor domain.
[0027] Preferably, the CAR-T cells are CD8 + T cell subsets.
[0028] Preferably, the CAR-T cells are CAR-T cells targeting carcinoembryonic antigen CEA.
[0029] Preferably, the tumor is a solid tumor.
[0030] As a specific example: the nucleotide sequence of the nucleic acid molecule encoding the CAR chimeric antigen receptor domain is shown in SEQ ID NO: 1.
[0031] Preferably, the plasmid contains the nucleotide sequence shown in SEQ ID NO:2.
[0032] A use of a recombinant lentivirus in the preparation of a product for CAR-T cell therapy of tumors, wherein the recombinant lentivirus carries a nucleic acid molecule encoding a UHRF1 protein and a nucleic acid molecule encoding a CAR chimeric antigen receptor domain, or expresses the UHRF1 protein and the CAR chimeric antigen receptor domain.
[0033] Preferably, the CAR-T cells are CD8 + T cell subsets.
[0034] Preferably, the CAR-T cells are CAR-T cells targeting carcinoembryonic antigen CEA.
[0035] Preferably, the tumor is a solid tumor.
[0036] As a specific example: the nucleotide sequence of the nucleic acid molecule encoding the CAR chimeric antigen receptor domain is shown in SEQ ID NO: 1.
[0037] A method for constructing CAR-T cells, comprising infecting T cells with the recombinant lentivirus.
[0038] Preferably, the T cells are CD8 + T cell subsets.
[0039] A CAR-T cell is a CAR-T cell that overexpresses UHRF1 protein and is obtained by infecting T cells with the recombinant lentivirus.
[0040] Preferably, the CAR-T cells are CD8 + T cell subsets.
[0041] The use of the CAR-T cells constructed by the method or the CAR-T cells in preparing tumor products also falls within the scope of protection of the present invention.
[0042] Preferably, the tumor is a solid tumor.
[0043] Compared with the prior art, the present invention has the following beneficial effects:
[0044] The present invention discloses the application of UHRF1 in the preparation of a synergist for CAR-T cell therapy of tumors. Overexpression of the epigenetic regulatory factor UHRF1 improves the infiltration ability of CAR-T cells in mice, solving the problem of poor infiltration ability of reinfused CAR-T cells in solid tumors; it also reduces the exhaustion, differentiation and apoptosis of CAR-T cells in mice, thereby enhancing the effect and killing ability of CAR-T cells in mice. The present invention enables the application of T cell adoptive therapy in solid tumors to have a better effect, and significantly enhances the anti-solid tumor ability of CAR-T cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 Schematic diagram of the constructed CEA-OE-CAR fragment overexpressing UHRF1.
[0046] Figure 2 Schematic diagram of the structure of the CEA-CAR lentiviral vector carrying mCherry and overexpressing UHRF1.
[0047] Figure 3 This is the titer measurement result of 293T cells infected with lentivirus after successful packaging; left: bright field view; right: mCherry fluorescence channel view.
[0048] Figure 4 The results of flow cytometry detection of infection efficiency; the Control group is the uninfected control CD8 + T cells, CEA-OE-CAR group and CEA-CAR group are CAR-T cells infected with two groups of CAR lentivirus; the value on the upper right is the mean fluorescence intensity MFI; the value above the gate is the positive rate of each group, that is, the infection efficiency.
[0049] Figure 5 The results of real-time fluorescence quantitative PCR and protein immunoblotting to detect UHRF1 expression; A: Real-time fluorescence quantitative PCR was used to detect the transcriptional expression level of CEA-scFv in each group of cells; B: Real-time fluorescence quantitative PCR was used to detect the transcriptional expression level of UHRF1 in each group of cells; C: Western blotting was used to detect the protein expression level of UHRF1 in each group of cells; ****P<0.0001.
[0050] Figure 6 The figure shows the effect of overexpression of UHRF1 on the proliferation of CEA-CAR-T cells cultured in vitro; A: absolute count results of CAR-T cells cultured in vitro on the fourth day after infection; B and C: flow cytometry detection of CAR-T cells cultured in vitro on the seventh day after infection, B: difference in CD98 expression between the two groups of cells, C: difference in Ki67 expression between the two groups of cells; *P<0.05, **P<0.01.
[0051] Figure 7 Figure 3 is the effect of overexpression of UHRF1 on the function of CEA-CAR-T cells cultured in vitro; A to C: CAR-T cells cultured in vitro were subjected to flow cytometry detection on the seventh day after infection, A: GZMB expression difference between the two groups of cells; B: IL-2 expression difference between the two groups of cells; C: TCF1 expression difference between the two groups of cells; *P < 0.05.
[0052] Figure 8 The figure shows the effect of overexpression of UHRF1 on the in vitro killing function of CEA-CAR-T cells; A: In vitro killing experiment, the test results are statistically obtained from 3 independent repeated experiments, and the samples for each test were provided by different healthy donors; B: ELISPOT test, the test results are statistically obtained from 3 independent repeated experiments, and the samples for each test were provided by different healthy donors; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0053] Fig. 9The figure shows the effect of overexpression of UHRF1 on the anti-tumor function of CEA-CAR-T cells in vivo; A: Tumor growth curve of mice after reinfusion of CAR-T cells in each group (CEA-CAR group: n=5; CEA-OE-CAR group: n=5); B: UHRF1 expression level of CAR-T cells in the spleen of mice after reinfusion. ***P<0.001.
[0054] Fig.10 The figure shows the effect of overexpression of UHRF1 on the proliferation of CEA-CAR-T cells in mice. AB: Flow cytometry detection of tumor-infiltrating CAR-T cells on the 8th day after reinfusion, A: Difference in Ki67 expression between the two groups of cells, B: Difference in apoptosis ratio between the two groups of cells. *P<0.05, **P<0.01.
[0055] Fig.11 Figure 3 is the effect of overexpression of UHRF1 on the function of CEA-CAR-T cells in mice; A to D: Flow cytometry detection of tumor-infiltrating CAR-T cells on the 8th day after reinfusion, A: Difference in IFN-γ expression between the two groups of cells, B: Difference in GZMB expression between the two groups of cells, C: Difference in IL-2 expression between the two groups of cells, B: Difference in TNF-α expression between the two groups of cells *P<0.05, **P<0.01, ***P<0.001. DETAILED DESCRIPTION
[0056] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0057] 1. Experimental Materials
[0058] (1) Human embryonic kidney epithelial cell line (293T) and CEA + Human colorectal cancer cell lines (LS174T) were purchased from ATCC. Competent cells DH5α were purchased from Beijing Qingke Biotechnology Co., Ltd. Peripheral blood T cells were derived from healthy donors.
[0059] (2) Three-plasmid lentiviral vector system: shuttle plasmid pLVX-IRES-mCherry, helper plasmid psPAX2 and envelope plasmid pMD2.G.
[0060] (3) Nod / scid immunodeficient mice: 6-8 weeks old, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. and routinely raised in an SPF-grade environment at the Experimental Animal Center of Sun Yat-sen University.
[0061] 2. Experimental instruments and software
[0062] (1) Flow cytometer BD LSRFortessa (BD Biosciences, USA)
[0063] (2) Multifunctional detector Promega GM3000 (Promega Corporation, USA)
[0064] (3) Real-time fluorescence quantitative PCR detector Bio-Rad CFX-96PCR (Bio-Rad, USA)
[0065] (4) Infrared laser dual-color imaging system Odyssey CLX imager (LI-COR, USA)
[0066] (5) Flow cytometry analysis software BD Flowjo V10 (BD Biosciences, USA)
[0067] (6) Data analysis software GraphPad Prism (GraphPad Software, USA)
[0068] 3. Main Reagents
[0069] 1. Antibodies
[0070]
[0071] 2. Compounds and Reagents
[0072]
[0073]
[0074] 3. Functional antibodies and cytokines
[0075]
[0076] 4. Detection kit
[0077]
[0078] Example 1 Construction and preparation of CAR lentiviral vector
[0079] 1. Construction of CAR chimeric antigen receptor domain (anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ)
[0080] A CAR lentiviral plasmid targeting carcinoembryonic antigen CEA was constructed using a single-chain variable region fragment (scFv-fragment, derived from the article published by Yazaki et al. doi:10.1093 / protein / gzs096) targeting CEA antigen.
[0081] 1. Experimental methods
[0082] After the scFv-fragment was codon-optimized, an IL-2 signal peptide sequence was added to the front end to form the basic CAR structure. By overlapping PCR, the Spacer sequence and transmembrane sequence (TM) derived from the CD8α molecule were inserted into the 5' end of the basic CAR structure, as well as intracellular signals designed based on the third-generation CAR structure, including: CD28 (nucleotides460-660; NM_006139.3), CD137 (nucleotides640-765; NM_001561.5), and CD3ζ (nucleotides160-492; NM_198053.2), to obtain a complete third-generation CAR structure (anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ), and its sequence was identified by Sanger sequencing.
[0083] 2. Experimental results
[0084] The Sanger sequencing results of anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ were consistent with expectations, and its sequence is shown in SEQ ID NO: 1.
[0085] 2. Construction of CEA-CAR plasmid and CEA-OE-CAR plasmid
[0086] 1. Experimental methods
[0087] The anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ (SEQ ID NO: 1) was connected to the downstream of the CMV promoter of the pLVX-IRES-mCherry vector by double enzyme digestion to obtain pLVX-anti CEA CAR-IRES-mCherry, i.e., CEA-CAR plasmid.
[0088] Using the constructed CEA-CAR plasmid, the full-length reading frame of UHRF1 (nucleotides114-2495; NM_001290051.2) was further expressed using the self-cleaving P2A peptide bicistronic element upstream of the open reading frame of the second-generation chimeric antigen expression vector to construct UHRF1 cds-P2A-anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ, as shown in the schematic diagram. Figure 1 As shown, the genetically modified T cells overexpress UHRF1 while expressing CAR, that is, the CEA-OE-CAR plasmid (plasmid structure as shown in Figure 2 and its sequence was identified by Sanger sequencing.
[0089] 2. Experimental results
[0090] The Sanger sequencing results were consistent with expectations, and the sequence of UHRF1 cds-P2A-anti CEA scFv-CD8αspacer-CD8αTM-CD28-CD137-CD3ζ was shown in SEQ ID NO: 2.
[0091] 3. Preparation of CEA-CAR plasmid and CEA-OE-CAR plasmid
[0092] The lentiviral vector plasmid obtained by gene cloning technology is obtained in batches through transformation, amplification and extraction. The competent cells used in the transformation process are DH5α. The lentiviral vector plasmid in the present invention is ampicillin-resistant, so ampicillin is added to the LB culture medium for screening. The amplified plasmid is extracted using the Endo-free Plasmid Maxi Kit (Omega Bio-tek, USA).
[0093] Example 2 Packaging of CAR Lentivirus
[0094] 1. Lentivirus packaging
[0095] 1. Experimental methods
[0096] To achieve better cell adhesion, 10 cm culture dishes were incubated with 1× poly k at 37°C for 20 minutes before plating, and poly k was recovered and the treated culture dishes were washed once with PBS. After digestion and counting of 293T cells with good growth status and negative mycoplasma test, 2×10 cells were inoculated in each treated 10 cm cell culture dish. 6 The next day, when the growth density of 293T cells reached about 80%, transfection was performed.
[0097] Prepare the following transfection mixtures:
[0098] Solution 1:
[0099]
[0100] Solution 2:
[0101] PEI-MAX 75μL
[0102] Opti-MEM 500 μL
[0103] After solution 1 and solution 2 were incubated at room temperature for 5 minutes, they were premixed and incubated at room temperature for another 20 minutes before being added to the prepared 10 cm culture dish.
[0104] After incubation in a 37°C cell culture incubator for 8 to 12 hours, the medium containing the transfection reagent was discarded and replaced with fresh DMEM high-glucose complete medium.
[0105] 2. Experimental results
[0106] After 24 hours of continuous culture, the cells were observed under a fluorescent microscope. Figure 3 As shown, red fluorescence appeared in the cells, indicating that mCherry was expressed, thus achieving lentiviral packaging.
[0107] 2. Preparation of Pseudovirus Concentrate
[0108] After about 48 hours of culture, the cell culture supernatant was collected to obtain the lentiviral solution (CEA-CAR group and CEA-OE-CAR group). In order to achieve efficient infection in the future, the lentiviral solution was concentrated. After filtering the lentiviral solution with a 0.45 μm filter membrane to remove cell debris, the concentration system was configured according to the following table:
[0109] 10 mL of the filtered culture supernatant, 3 mL of 50% (w / v) PEG6000, 1.28 mL of 4M NaCl and 1.37 mL of 1×PBS were added.
[0110] Mix the prepared concentrated system by inversion and place at 4 degrees overnight. Then centrifuge the concentrated system at 4000 rcf for 40 minutes at 4°C. Carefully remove the supernatant, add KBM581 medium of one-thirtieth of the original culture medium system, resuspend the precipitate to obtain the pseudovirus concentrate (30 times concentrated), which can be directly infected or frozen at -80°C.
[0111] Example 3 Preparation of CAR-T cells
[0112] 1. Extraction of peripheral blood mononuclear cells (PBMC) from healthy subjects.
[0113] (1) Collect 50 ml of peripheral blood from healthy volunteers using EDTA anticoagulant tubes;
[0114] (2) Centrifugation at 450 g for 10 min at room temperature to separate the upper plasma layer from the lower blood cells;
[0115] (3) After collecting the upper plasma layer, dilute the peripheral blood cells in the lower layer with twice the volume of PBS solution;
[0116] (4) Take a 50 mL centrifuge tube, add about 25 mL of human peripheral blood lymphocyte separation fluid (hereinafter referred to as separation fluid), and use a Pasteur pipette to slowly add the diluted blood cells along the junction of the tube wall and the liquid surface to the top of the separation fluid, and avoid mixing the separation fluid and the blood sample;
[0117] (5) Centrifuge at 1440 rcf for 25 minutes at room temperature, setting the speed to 2 and the speed to 0;
[0118] (6) After centrifugation, use a sterile Pasteur pipette to aspirate the thin white layer of mononuclear cells in the middle into a new centrifuge tube, add excess PBS to wash the cells twice, and the resulting cell pellet is human PBMC.
[0119] 2. CD8 in PBMC + Sorting and enrichment of T cells.
[0120] (1) Count the human PBMCs obtained and resuspend the cells in PBS to a cell concentration of 5×10 7 cells / mL;
[0121] (2) Add 75 μL of biotin-coupled CD8 + T lymphocyte enrichment cocktail (Reagent in Human CD8 T Lymphocyte Enrichment Set, BD) and incubate on ice for 15 min;
[0122] (3) Add excess PBS to wash the unbound cocktail and centrifuge at 450 g for 5 minutes at room temperature;
[0123] (4) After removing the supernatant, thoroughly vortex the streptavidin-coupled magnetic beads and add an equal amount of magnetic beads as the cocktail to resuspend the cell pellet. Incubate at room temperature for 30 minutes, mixing every 10 minutes.
[0124] (5) Add 1-2 mL of PBS to dilute the cell suspension and transfer it to a clean flow tube. Place it on the cell sorting magnetic stand for 6-8 minutes until the magnetic beads are fully bound to the tube wall;
[0125] (6) Carefully aspirate the liquid in the tube into a new flow tube and place it on the magnetic rack for 6-8 minutes to completely remove the magnetic beads. The remaining cells in the cell suspension are high-purity CD8 + T cells.
[0126] 3. Lentivirus infection of activated T cells.
[0127] (1) Resuspend the obtained CD8 + T cells, 1×10 6 / mL concentration was plated in a 12-well plate, 1mL of the system was added to each well, and anti-human CD3 and CD28 antibodies were added to the plate at a final concentration of 1μg / mL to activate CD8 + T cells;
[0128] (2) The CEA-CAR group and CEA-OE-CAR group lentiviral concentrates packaged in Example 2 were diluted 4 times with KBM581 medium and 1 mL was dispensed into each well. Polybrene was added to each well at a final concentration of 6 μg / mL and mixed thoroughly.
[0129] (3) Centrifuge at 500 g at 30°C for 90 minutes, set the speed to 2 and then to 2. After centrifugation, place the cells in a 37°C cell culture incubator and culture overnight.
[0130] (4) After 8 to 12 hours, carefully collect the cells to prevent PEG 6000 deposited at the bottom of the well from being carried into the new well, discard the medium containing the lentivirus, and replace it with fresh KBM581 complete medium;
[0131] (5) Count the cells, based on 5×10 5 / mL concentration was plated into a new 12-well plate, with 1mL system in each well, and IL-2 was added for amplification culture. Subsequently, the wells were supplemented or half-changed with fresh KBM581 medium containing IL-2 every other day to maintain the growth and expansion of CAR-T cells.
[0132] Example 4 Examination of infection efficiency of CAR-T cells
[0133] 1. Flow cytometry to examine the infection efficiency of CAR-T cells
[0134] 1. Experimental methods
[0135] On the third day after the lentiviral infection activated T cells in Example 3, the uninfected CD8 +T cells (Control group) and infected CAR-T cells (CEA-CAR group and CEA-OE-CAR group), use PBS buffer to prepare Fixable Viability Dye (FVD) and anti-hCD8 antibody premix to resuspend the cell pellet and stain on ice or at 4 degrees for half an hour for labeling. After adding excess PBS to wash the antibody, resuspend the cells in 200 μL PBS and analyze the infected T cells to detect the mCherry expression.
[0136] 2. Experimental results
[0137] like Figure 4 As shown, the detection found that CD8 + In the T cell subsets, compared with the Control group, the expression of mCherry in the CEA-CAR group and the CEA-OE-CAR group was significantly increased, and the positive rate was about 30%, that is, the infection efficiency was about 30%.
[0138] 2. qPCR detection of CEA-scFv and UHRF1 expression
[0139] On the third day after the lentivirus-activated T cells were infected in Example 3, 1×10 6 After removing the culture medium from T cells, 1 ml of Trizol reagent was added, and the cellular RNA was extracted by the phenol-chloroform method, and cDNA was obtained using 1st Strand cDNA Synthsis Kit (Novozymes) for quantitative detection by qPCR.
[0140] The primers are as follows:
[0141] ceascfv-F: AGAGCAAGCAACCTCGAGTC;
[0142] ceascfv-R: TGGCCAAATGTGTAGGGGTC;
[0143] hu-uhrf1-F:GCCATACCCTCTCGACTACG;
[0144] hu-uhrf1-R: GCCCCAATTCCGTCTCATCC.
[0145] 2. Experimental results
[0146] like Figure 5 A and Figure 5As shown in B, compared with the control group, in which no CEA-scFv expression could be detected, both groups of CAR-T cells (CEA-CAR group and CEA-OE-CAR group) expressed CEA-scFv to a certain extent, thus achieving the construction of CAR-T cells. And compared with the CEA-CAR group, the expression levels of CEA-scFv and UHRF1 in the CEA-OE-CAR group were significantly increased, thus achieving the goal of overexpressing UHRF1.
[0147] 3. Detection of UHRF1 expression by Western blotting
[0148] On the third day after the lentivirus infected activated T cells in Example 3, 1×10 6 After the culture medium of T cells was removed and washed once with PBS, the cells were lysed to obtain the denatured proteins in the cells. The proteins were separated by SDS-PAGE electrophoresis and transferred to the NC membrane. After blocking and washing the membrane, the primary antibody corresponding to the detection protein was added at a dilution of 1:1000 and incubated at 4°C overnight. Then, the secondary antibody corresponding to the species of the primary antibody was added and incubated at room temperature for 1 hour and imaging was performed.
[0149] 2. Experimental results
[0150] like Figure 5 As shown in C, the expression level of UHRF1 in the CEA-OE-CAR group was much higher than that in the other groups, confirming the overexpression of UHRF1 at the protein level.
[0151] Example 5 Effect of overexpression of UHRF1 on CAR-T cells
[0152] 1. Effect of overexpression of UHRF1 on the absolute number of CAR-T cells
[0153] 1. Experimental methods
[0154] On the 4th day after the lentiviral infection activated T cells in Example 3, the CAR-T cells in each well were collected and completely resuspended, and counted using a fully automatic cell counter to analyze the absolute number of cells in each well.
[0155] 2. Experimental results
[0156] The results are as follows Figure 6 As shown in A, compared with the CEA-CAR group, the number of cells in the CEA-OE-CAR group increased significantly, indicating that the cells in the CEA-OE-CAR group had a stronger proliferation ability, and overexpression of UHRF1 enhanced the proliferation ability of CAR-T cells.
[0157] 2. Effect of overexpression of UHRF1 on CAR-T cell proliferation indicators
[0158] 1. Experimental methods
[0159] On the 7th day after the lentiviral infection activated T cells in Example 3, the cultured CAR-T cells were collected for flow cytometry detection.
[0160] (1) Sample processing: On the 7th day of in vitro culture, the cell suspensions of each group in the 12-well plate were mixed and counted, and 1×10 6 Place CAR-T cells into a clean EP tube and resuspend the cells with 50 μL PBS;
[0161] (2) Labeling cell surface antibodies: Add cell surface molecule flow cytometry antibodies of corresponding dilution ratio to each group of sample tubes and incubate at 4 degrees in the dark for 30 minutes. In this experiment, the flow cytometry antibodies are FVD, anti-CD8 and anti-CD98;
[0162] (3) Washing: Add 1 mL of PBS buffer to each tube, mix well, centrifuge at 450 g for 5 minutes at room temperature, and discard the supernatant;
[0163] (4) Fixation and permeabilization: Use Foxp3 / Transcription Factor Staining Buffer Set to fix and permeabilize cell surface molecules. Prepare 1× fixative according to the kit instructions. Add 200 μL of 1× fixative to each tube and let stand overnight at 4 degrees. Then add 1 mL of 1× permeabilization buffer to each tube for resuspending and mixing. Centrifuge at 450 g for 5 minutes at room temperature, discard the supernatant, and resuspend the cells with 50 μL of 1× permeabilization buffer. Subsequent antibody labeling must be performed in the 1× permeabilization buffer environment.
[0164] (5) Labeling intracellular antibodies: Add intracellular molecule flow cytometry antibodies of corresponding dilution ratios to each group of sample tubes, and incubate at 4 degrees in the dark for 30 minutes. The flow cytometry antibody is anti-Ki67;
[0165] (6) Detection and analysis: Resuspend the labeled cells in 200 μL PBS buffer and analyze them on a flow cytometer. Flowjo V10 software was used to analyze CD8 + Molecular expression in T cell subsets.
[0166] 2. Experimental results
[0167] The results are as follows Figure 6 B and Figure 6As shown in Figure C, compared with the CEA-CAR group, the CD98 and Ki67 in the CEA-OE-CAR group overexpressing UHRF1 were significantly increased. Ki67 is a cell proliferation-related transcription factor that characterizes the proliferation potential of cells; CD98 is a surface molecule highly expressed in actively proliferating cells, responsible for transporting amino acids, and characterizes the proliferation strength of cells. It was further confirmed at the molecular level that overexpression of UHRF1 enhanced the proliferation ability of CAR-T cells.
[0168] 3. Detection of CAR-T cell function
[0169] 1. Experimental methods
[0170] On the 7th day after the lentiviral infection activated T cells in Example 3, the cultured CAR-T cells were collected for flow cytometry detection.
[0171] (1) In vitro reactivation: On the 7th day of in vitro culture, the cell suspensions of each group in the 12-well plate were mixed and counted, and 1×10 6 CAR-T cells were cultured in RPMI1640 complete medium and incubated with Cell Stimulation Cocktail (plus protein transport inhibitors) (500X) for 6 hours;
[0172] (2) Labeling antibodies: Collect the restimulated samples according to the method described in Example 4 and perform cell surface marker staining, and then label FVD and anti-CD8;
[0173] (3) Fixation and permeabilization: Use Intracellular Fixation & Permeabilization Buffer Set to fix and permeabilize cell surface molecules. Resuspend with 200 μL IC buffer and fix overnight at 4°C. Add 1 mL 1× permeabilization buffer to each tube and resuspend and mix. Centrifuge at 450 g for 5 minutes at room temperature, discard the supernatant, and resuspend the cells with 50 μL 1× permeabilization buffer. Subsequent antibody labeling must be performed in the 1× permeabilization buffer environment.
[0174] (4) Labeling intracellular antibodies: Add intracellular molecule flow cytometry antibodies of corresponding dilution ratios to each group of sample tubes and incubate at 4 degrees in the dark for 30 minutes. The flow cytometry antibodies are anti-IL-2, anti-GZMB, and anti-TCF1.
[0175] (5) Detection and analysis were performed according to the method described in Example 4.
[0176] 2. Experimental results
[0177] The results are as follows Figure 7As shown in the figure, compared with the CEA-CAR group, the secretion of cytokines such as GZMB and IL-2, which play an important role in immune response and effector killing, was increased in the CEA-OE-CAR group ( Figure 7 A and Figure 7 -B), and the expression of TCF-1, a transcription factor related to functional effects, was also elevated in the CEA-OE-CAR group ( Figure 7 C), indicating that the immune function of the CEA-OE-CAR group was significantly better than that of the CEA-CAR group. Overexpression of UHRF1 affected the function of CAR-T cells, enhancing the immune response and effector killing function of CAR-T cells.
[0178] Example 6 Expression of UHRF1 enhances CAR-T cell killing ability
[0179] 1. Effect of UHRF1 expression on the killing efficiency of CAR-T cells in vitro
[0180] 1. Experimental methods
[0181] On the 7th day of in vitro culture, the cultured CAR-T cells were collected for killing experiments.
[0182] (1) Cell preparation: DMEM high-glucose complete medium is used to culture CEA + Collect LS174T human colorectal cancer cell line cells, count the cells and adjust the LS174T cell density to 2 × 10 5 / mL; collect the cultured CAR-T cells from each group and adjust the CAR-T cell density to 3x10 6 / mL;
[0183] (2) Cell plating: cells were plated at a ratio of 16:1 (1.6×10 5 CAR-T: 10 4 LS 174T), 8:1(8×10 4 CAR-T: 10 4 LS174T), 4:1(4×10 4 CAR-T: 10 4 LS 174T), 2:1(2×10 4 CAR-T: 10 4 LS174T) in a proportion of 1:1 and 1:1, and then added to a total volume of 150 μL. The background control group was treated with an equal volume of KBM581 medium; the volume correction control group was treated with an equal volume of KBM581 medium; the effector cell self-release group was treated with an equal amount of CAR-T cells and KBM581 medium to make up the volume; the target cell self-release group was treated with 10 4 target cells; the maximum release group of target cells is 10 4Each group has 3 secondary wells;
[0184] (3) Cell incubation: After adding the sample, centrifuge at 500 rcf for 3 minutes at room temperature, and incubate at the bottom of a U-bottom 96-well plate. Incubate in a 37°C incubator for 24 hours;
[0185] (4) Cell lysis: The next day, 16.5 μL of 10× cell lysis buffer was added to the target cell maximum release group and volume correction control group and incubated for another 1 hour;
[0186] (5) Cell sampling and detection: Before sampling, the culture plate was centrifuged at 500g for 5 minutes at room temperature. Subsequently, 30 μL of supernatant was taken from each well and transferred to a new flat-bottom 96-well plate, and 30 μL of LDH reaction substrate was added. After reacting at room temperature in the dark for 30 minutes, 30 μL of stop solution was added and the absorbance reading at 490 nm was detected; the specific killing efficiency of CAR-T cells against target cells was calculated by the following formula.
[0187]
[0188] 2. Experimental results
[0189] The results are as follows Figure 8 As shown in A, as the ratio of CAR-T cells to LS174T target cells increases, the specific killing rate also increases; and the specific killing rate of the CEA-OE-CAR group is significantly higher than that of the CEA-CAR group. It can be seen that the specific killing ability of the CEA-OE-CAR group cells is significantly higher than that of the CEA-CAR group cells, that is, the in vitro killing experiment shows that overexpression of UHRF1 can significantly enhance the anti-tumor ability of CAR-T cells.
[0190] 2. Effect of cytokine release of UHRF1-expressing CAR-T cells
[0191] 1. Experimental methods
[0192] On the 7th day of in vitro culture, the cultured CAR-T cells were collected and tested for IFNγ secretion by ELISPOT assay. The ELISPOT assay was completed using Human IFN-γ Precoated ELISPOT Kit (Dayou). The specific steps were referred to the instructions of the kit. 4 LS174T target cells were added to the effector target cell groups with different ratios, and the CAR-T cells of each group were added to different concentrations. After incubation and color development, the spots were counted to detect the IFNγ secretion at the single-cell level.
[0193] 2. Experimental results
[0194] The results are as follows Figure 8As shown in B, as the ratio of CAR-T cells to LS174T target cells increased, the number of cells secreting IFNγ also increased with the increase of concentration, showing effector activity; and the IFNγ in the CEA-OE-CAR group + The cell numbers were higher than those in the CEA-CAR group, showing significantly enhanced effector ability, indicating that CAR-T cells overexpressing UHRF1 have stronger effector ability and a higher anti-tumor response ratio.
[0195] Example 7 Overexpression of UHRF1 improves the anti-tumor ability of CAR-T cells
[0196] 1. Experimental Methods
[0197] The phenomenon that overexpression of UHRF1 improves the anti-tumor ability of CAR-T cells was verified in vivo through the construction of humanized tumor models and adoptive transfer experiments.
[0198] (1) In vivo model construction: The human colorectal cancer cell line LS174T cells were revived and cultured and expanded; the cultured LS174T cells were digested and the culture medium was discarded, then washed with PBS and counted, and then resuspended with PBS to a cell concentration of 6×10 6 / mL; several 6-8 week old Nod / scid mice with similar body weight were selected, the tumor-bearing site on the right groin was shaved and 100 μL / mouse of the prepared tumor cell suspension was injected subcutaneously. The tumor model was successfully constructed when a spherical swelling appeared under the skin.
[0199] (2) CAR-T adoptive transfusion: About 7 days after tumor loading or when the mean tumor volume reached 100, the in vitro expanded CAR-T cells were transfused into groups. Before transfusion, they were treated once with human peripheral blood lymphocyte separation fluid to remove impurities. Each mouse was transfused with 1x10 6 cell.
[0200] (3) Drawing tumor growth curve: The tumor size of mice was measured on the day of infusion and every other day after infusion until the tumor size reached the humane endpoint, and the experimental mice were euthanized. The tumor size was calculated using the following formula (where a and b represent length and width, respectively):
[0201]
[0202] (4) The spleen tissue of the experimental mice was collected, and the single cell suspension was obtained after grinding and digestion for flow cytometry as described above to detect the expression of UHRF1 in CAR-T cells in vivo. In this embodiment, the flow cytometry antibodies are FVD, anti-CD8 and anti-UHRF1.
[0203] 2. Experimental Results
[0204] The results are as follows Fig. 9 As shown in A, after reinfusion of CAR-T, it was found that the tumor growth of mice in the CEA-OE-CAR group overexpressing UHRF1 was significantly slowed down and inhibited compared with the CEA-CAR group. The tumor size of mice infused with CEA-CAR cells reached the humane endpoint within 15 days after reinfusion, while the tumor size of mice infused with CEA-OE-CAR cells reached the humane endpoint 21 days after reinfusion. In vivo experiments have shown that CAR-T cells overexpressing UHRF1 have stronger anti-tumor ability and can better inhibit tumor growth.
[0205] And, if Fig. 9 As shown in B, the CEA-OE-CAR group cells overexpressing UHRF1 still maintained overexpression of UHRF1 after reinfusion. Compared with the CEA-CAR group, the UHRF1 expression level of the CEA-OE-CAR group cells in the spleen of mice after reinfusion was significantly increased.
[0206] Example 8 Effect of UHRF1 expression on tumor-infiltrating CAR-T cells
[0207] 1. Experimental Methods
[0208] The tumor and reinfusion model was constructed using the method of Example 7. About 8 days after reinfusion, when the tumor volume fraction was about 800, the spleen was ground and the tumor was digested to obtain the respective single cell suspensions. The method of Example 4 was used to perform flow cytometry detection of proliferation, function, apoptosis and other indicators of tumor-infiltrating CAR-T cells in each group of mice, wherein the detection of apoptosis indicators needed to be completed in 1×Annexin Vbinding buffer.
[0209] 2. Experimental Results
[0210] The results are as follows Fig.10 As shown in A, the Ki67 expression in the CEA-OE-CAR group was significantly higher than that in the CEA-CAR group, indicating that CAR-T cells overexpressing UHRF1 also have stronger proliferation ability after infiltration into the tumor microenvironment after reinfusion; Fig.10 As shown in B, the positive rate of Annexin V in the CEA-OE-CAR group was significantly lower than that in the CEA-CAR group, indicating that CAR-T cells overexpressing UHRF1 were less likely to undergo apoptosis when infiltrating into the tumor microenvironment after reinfusion, that is, compared with the CEA-CAR group, the CEA-OE-CAR group had less apoptosis, enhanced proliferation ability, and better survival ability.
[0211] like Fig.11As shown in the figure, the secretion capacity of IFN-γ, GZMB, IL-2, TNF-α and other function-related cytokines in the CEA-OE-CAR group was significantly enhanced compared with the CEA-CAR group, indicating that compared with the CEA-CAR group, CAR-T cells overexpressing UHRF1 had more active immune responses and stronger effector ability in the tumor microenvironment after reinfusion. That is, overexpression of UHRF1 improves the survival and effector ability of CEA-CAR-T cells in vivo and enhances their anti-tumor ability.
Claims
1. Application of UHRF1 protein in the preparation of CAR-T cell enhancers for tumor therapy.
2. The use according to claim 1, characterized in that: The CAR-T cells are CD8 + T cell subsets.
3. The use according to claim 1 or 2, characterized in that: The CAR-T cells are CAR-T cells targeting carcinoembryonic antigen CEA.
4. Use of a plasmid in preparing a product for treating tumors with CAR-T cells, characterized in that: The plasmid contains a nucleic acid molecule encoding the UHRF1 protein and a nucleic acid molecule encoding the CAR chimeric antigen receptor domain.
5. The use according to claim 4, characterized in that: The plasmid contains the nucleotide sequence shown in SEQ ID NO:
2.
6. Use of a recombinant lentivirus in the preparation of a product for CAR-T cell therapy of tumors, characterized in that: The recombinant lentivirus carries a nucleic acid molecule encoding the UHRF1 protein and a nucleic acid molecule encoding the CAR chimeric antigen receptor domain.
7. A method for constructing CAR-T cells, characterized in that: The recombinant lentivirus described in claim 6 is used to infect T cells to obtain the product.
8. The use according to claim 7, characterized in that: The T cells are CD8 + T cell subsets.
9. A CAR-T cell, characterized in that: The CAR-T cells overexpressing UHRF1 protein are obtained by infecting T cells with the recombinant lentivirus described in claim 6.
10. Use of the CAR-T cells constructed by the method of claim 7 or 8 or the CAR-T cells of claim 9 in preparing tumor products.
Citation Information
Patent Citations
VC-CAR molecule and application thereof to HIV-1 infection cell clearing
CN106279432A
Chimeric antigen receptor for identifying carcino-embryonic antigens and application of chimeric antigen receptor
CN107033248A
Methods for treating multiple myeloma
WO2024059494A1
